SCHEMBL411007

SCHEMBL411007

CCOCCOC(=O)N1CC=Cc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 1/20 0.44
P2RX4 Q99571 5/20 0.39
ALDH1A1 P00352 3/20 0.38
BCHE P06276 3/20 0.36
P2RX1 P51575 2/20 0.36
P2RX3 P56373 2/20 0.36
PTBP1 P26599 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
P2RX7 Q99572 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
ADORA1 P30542 1/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
NOTUM Q6P988 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29639604 1.00 SMN1; SMN2 (0.44) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE
SCHEMBL29549990 0.89 SMN1; SMN2 (0.53) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE
SCHEMBL205655 0.89 SMN1; SMN2 (0.53) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE
SCHEMBL6110992 0.88 SMN1; SMN2 (0.44) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE
SCHEMBL3638042 0.87 LMNA (0.69) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE
SCHEMBL3719677 0.86 BCHE (0.50) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE
SCHEMBL6110401 0.79 P2RX4 (0.64) SMN1; SMN2LMNAP2RX4ALDH1A1P2RX1
SCHEMBL27785934 0.78 P2RX4 (0.58) SMN1; SMN2LMNAP2RX4BCHEP2RX1
SCHEMBL28802473 0.77 P2RX4 (0.63) SMN1; SMN2P2RX4ALDH1A1P2RX1P2RX3
SCHEMBL22264116 0.76 P2RX4 (0.41) SMN1; SMN2LMNAP2RX4ALDH1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339906-A1 A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF PI INDUSTRIES LTD. (IN) 2023-10-26 US claimed
CN-112830984-B Design and preparation method of non-woven fabric material capable of being disinfected by chlorine dioxide 厦门市添孚卫生科技有限公司 2023-09-05 CN claimed
CN-111094281-B Chemical process for preparing monolactam antibiotics and intermediates thereof 诺华股份有限公司 2023-08-29 CN claimed
US-11414411-B2 Chemical process for manufacturing monobactam antibiotic and intermediates thereof NOVARTIS AG (CH) 2022-08-16 US claimed
EP-3661933-B1 PROCESS FOR PREPARING 1-(((Z)-(1-(2-AMINOTHIAZOL-4-YL)-2-OXO-2-(((3S,4R)-2-OXO-4-((2-OXOOXAZOLIDIN-3-YL)METHYL)-1-SULFOAZETIDIN-3- YL)AMINO)ETHYLIDENE)AMINO)OXY)CYCLOPROPANE CARBOXYLIC ACID NOVARTIS AG (CH) 2022-03-23 EP claimed
EP-3927685-A1 A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF PI Industries Ltd. (IN) 2021-12-29 EP claimed
CN-112830984-A Design and preparation method of novel non-woven fabric material capable of being disinfected by chlorine dioxide 厦门市添孚卫生科技有限公司 2021-05-25 CN claimed
US-20200239461-A1 CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD. (CN) 2020-07-30 US claimed
CN-111094281-A Chemical process for the preparation of monobactam antibiotics and intermediates thereof 诺华股份有限公司 2020-05-01 CN claimed
EP-1684816-B1 METHODS OF PREPARING CROSSLINKED MATERIALS AND BIOPROSTHETIC DEVICES MEDTRONIC INC (US) 2009-05-06 EP claimed
EP-1641754-B1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL SCHERING CORP (US) 2008-03-26 EP claimed
US-7326795-B2 Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl SCHERING CORPORATION (US) 2008-02-05 US claimed
EP-1641754-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL SCHERING CORPORATION (US) 2006-04-05 EP claimed
EP-1556039-A2 PROCESS FOR THE PREPARATION OF TRI-NITROGEN CONTAINING HETEROARYL-DIAMINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS AND METHODS OF PRODUCING PHARMACEUTICAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-27 EP claimed
US-20050059800-A1 Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl SCHERING CORPORATION 2005-03-17 US claimed
WO-2004113294-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3-AZABICYCLO[3, 1, 0]HEXANE-2-CARBOXAMIDE, N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3-[(2S)-2-[[[1, 1-DIMETHYLETHYL]AMINO]CARBONYLAMINO]-3, 3-DIMETHYL-1-OXOBUTYL]-6, 6-DIMETHYL SCHERING CORPORATION (US) 2004-12-29 WO claimed
WO-2004032875-A2 PROCESS FOR THE PREPARATION OF TRI-NITROGEN CONTAINING HETEROARYL-DIAMINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS AND METHODS OF PRODUCING PHARMACEUTICAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-22 WO claimed
US-20250152734-A1 USES AND FORMULATIONS OF CAMPTOTHECIN (CPT)-CONTAINING NANOPARTICLES DANTARI INC (US) 2025-05-15 US disclosed
US-4076822-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1978-02-28 US disclosed
US-3980657-A FIBRINOLYTICS, THROMBOLYTICS, ANTIPHLOGISTICS, ANALGESICS CIBA-GEIGY CORPORATION (US) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414411-B2 Chemical process for manufacturing monobactam antibiotic and intermediates thereof SRR, DCXR, JMJD6 SMN1; SMN2 3344/4885LMNA 4393/4885P2RX4 2256/4885
US-20050059800-A1 Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl AZI2, ALKBH1, ALKBH5 SMN1; SMN2 535/4885LMNA 1643/4885P2RX4 1818/4885
US-20200239461-A1 CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF SRR, DCXR, JMJD6 SMN1; SMN2 3344/4885LMNA 4393/4885P2RX4 2256/4885
US-20250152734-A1 USES AND FORMULATIONS OF CAMPTOTHECIN (CPT)-CONTAINING NANOPARTICLES MUC1, TOP2A, TOP1 SMN1; SMN2 3465/4885LMNA 1277/4885P2RX4 4147/4885
US-20230339906-A1 A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF ASS1, ARG1, NQO2 SMN1; SMN2 4835/4885LMNA 3246/4885P2RX4 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.